Effects of Concomitant Medication Use on Gefitinib-Induced Hepatotoxicity

Soyeon Cho, Jeong Yee, Jae Youn Kim, Sandy Jeong Rhie, Hye Sun Gwak

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Gefitinib is a drug used for the treatment of non–small cell lung cancer (NSCLC) patients. Severe hepatotoxicity was observed, but only a few cases have been reported on the hepatotoxicity of gefitinib. This study aimed to investigate the association between gefitinib-induced hepatotoxicity and various factors including concomitant medications in lung cancer patients. From January 2013 to December 2014, a retrospective study was performed with NSCLC patients who were treated with gefitinib. Associations between hepatotoxicity and various factors including concomitant drugs were analyzed. Based on multivariate models, it was found that H2 antagonists, proton pump inhibitors (PPIs), and H2 antagonists or PPIs increased hepatotoxicity by about 1.5- to 1.7-fold. Patients younger than 65 years showed 1.6 times higher hepatotoxicity than those older than 65 years. Patients with EGFR mutations had around 2-fold higher hepatotoxicity, and the percentage of incidence of hepatotoxicity because of exon 19 deletion was 32.7%. Our study showed that anti-acid-secreting agents in addition to age younger than 65 years and EGFR mutation were associated with gefitinib-induced hepatotoxicity. Thus, close monitoring of liver function is recommended, especially for patients using anti-acid-secreting agents.

Original languageEnglish
Pages (from-to)263-268
Number of pages6
JournalJournal of Clinical Pharmacology
Issue number2
StatePublished - Feb 2018

Bibliographical note

Publisher Copyright:
© 2017, The American College of Clinical Pharmacology


  • EGFR mutation
  • H2 antagonist
  • gefitinib
  • hepatotoxicity
  • proton pump inhibitor


Dive into the research topics of 'Effects of Concomitant Medication Use on Gefitinib-Induced Hepatotoxicity'. Together they form a unique fingerprint.

Cite this